Özet:

The article provides an overview of programs, plans, tools of scientific and technological, innovation and industrial policy aimed at creating and producing new drugs in China; it is substantiated that the Chinese government uses an integrated approach in the implementation of mechanisms to protect and strengthen the pharmaceutical industry. It is demonstrated that the Chinese government provides business support in the form of subsidies, tax incentives, the creation of special zones for the development of high-tech industries, and helps to attract foreign direct investment in contract manufacturing and research and development, accompanied by technology transfer; through the public procurement system, a program for the development of endogenous innovations is implemented through the provision of price preferences, and advanced foreign technologies are involved. State support contributed to an increase in the level of localization of production and an increase in the number of jobs, an increase in the added value of production and the competitiveness of the pharmaceutical industry, the formation of scientific and technical competencies and the development of technologies, the creation of objects of intellectual property rights. The Chinese model of investment and innovative development, relying on the use of external technological, production, human resources, has made it possible to form a high-tech pharmaceutical sector capable of producing endogenous innovations. Given the objectives of the policy documents, Chinese enterprises are encouraged to invest in other countries in the interests of the development of Chinese pharmaceuticals.

Anahtar Kelimeler: